CuraSen Therapeutics, Inc. is developing drugs targeting a novel mechanism in the brain to restore function, improve symptoms and modify disease in a range of neurodegenerative diseases, including orphan disorders as well as Parkinson's Disease and Alzheimer's Disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/17/18 | $54,500,000 | Series A |
Alta Partners Johnson & Johnson Innovation Longitude Capital New Leaf Venture Partners  Pappas Capital Tekla Capital Management | undisclosed |
